Vaccine and Infectious Disease Division

2009 VIDD Publications

1. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM, Dye C, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA. 2009;106(33):13980-5.

2. Alsallaq RA, Cash B, Weiss HA, Longini IM, Omer SB, Wawer MJ, et al. Quantitative assessment of the role of male circumcision in HIV epidemiology at the population level. Epidemics. 2009;1(3):139-52.

3. Aubert M, Yoon M, Sloan DD, Spear PG, Jerome KR. The virological synapse facilitates herpes simplex virus entry into T cells. Journal of virology. 2009;83(12):6171-83.

4. Barouch DH, Liu J, Lynch DM, O'Brien KL, La Porte A, Simmons NL, et al. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. Journal of virology. 2009;83(18):9584-90.

5. Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol. 2009;170(6):679-86.

6. Berrington WR, Jerome KR, Cook L, Wald A, Corey L, Casper C. Clinical correlates of herpes simplex virus viremia among hospitalized adults. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009;49(9):1295-301.

7. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711-9.

8. Boily M-C, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. The Lancet infectious diseases. 2009;9(2):118-29.

9. Brainard DM, Seung E, Frahm N, Cariappa A, Bailey CC, Hart WK, et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. Journal of virology. 2009;83(14):7305-21.

10. Chan YR, Liu JS, Pociask DA, Zheng M, Mietzner TA, Berger T, et al. Lipocalin 2 is required for pulmonary host defense against Klebsiella infection. Journal of immunology (Baltimore, Md : 1950). 2009;182(8):4947-56.

11. Chattopadhyay PK, Betts MR, Price DA, Gostick E, Horton H, Roederer M, et al. The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol. 2009;85(1):88-97.

12. Cook L, Atienza EE, Bagabag A, Obrigewitch RM, Jerome KR. Comparison of methods for extraction of viral DNA from cellular specimens. Diagn Microbiol Infect Dis. 2009;64(1):37-42.

13. Corey L, McElrath MJ, Kublin JG. Post-step modifications for research on HIV vaccines. AIDS (London, England). 2009;23(1):3-8.

14. Corey L, Wald A. Maternal and neonatal herpes simplex virus infections. N Engl J Med. 2009;361(14):1376-85.

15. Crawford DC, Zheng N, Speelmon EC, Stanaway I, Rieder MJ, Nickerson DA, et al. An excess of rare genetic variation in ABCE1 among Yorubans and African-American individuals with HIV-1. Genes Immun. 2009;10(8):715-21.

16. Dimitrov DT, Hallam TG. Effects of immune system diversity and physical variation ofimmunotypic mixing on the dynamics of rabies in bats. J Biol Dyn. 2009;3(2-3):164-79.

17. Doehle BP, Hladik F, McNevin JP, McElrath MJ, Gale M. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. Journal of virology. 2009;83(20):10395-405.

18. Engelhard D, Akova M, Boeckh M, Freifeld A, Sepkowitz K, Viscoli C, et al. Bacterial infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44(8):467-70.

19. Englund J, Zerr D, Heath J, Pergam SA, Kuypers J, Yager JE, et al. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep. 2009;58(32):893-6.

20. Fesinmeyer MD, Mehta V, Tock L, Blough D, McDermott C, Ramsey SD. Completion of radiotherapy for local and regional head and neck cancer in medicare. Arch Otolaryngol Head Neck Surg. 2009;135(9):860-7.

21. Fredricks DN, Fiedler TL, Thomas KK, Mitchell CM, Marrazzo JM. Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis as assessed by quantitative PCR. J Clin Microbiol. 2009;47(3):721-6.

22. Gardella C, Krantz E, Daruthayan C, Drolette L, Corey L, Wald A. The acceptance of HSV-testing partners of HSV-2 seronegative pregnant women. Sexually transmitted diseases. 2009;36(4):211-5.

23. Gilbert PB, Qin L, Self SG. Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'. Statistics in medicine. 2009;28(4):716-9.

24. Gilbert PB, Sato A, Sun X, Mehrotra DV. Efficient and robust method for comparing the immunogenicity of candidate vaccines in randomized clinical trials. Vaccine. 2009;27(3):396-401.

25. Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, et al. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw. 2009;7 Suppl 3:S1-S32; quiz S3-S5.

26. Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, et al. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. Journal of virology. 2009;83(17):8925-37.

27. Gurunathan S, Habib RE, Baglyos L, Meric C, Plotkin S, Dodet B, et al. Use of predictive markers of HIV disease progression in vaccine trials. Vaccine. 2009;27(14):1997-2015.

28. Halloran ME, Holmes EC. Invited commentary: Evaluating vaccination programs using genetic sequence data. Am J Epidemiol. 2009;170(12):1464-6; discussion 7-8.

29. Han J-Y, Miller SA, Wolfe TM, Pourhassan H, Jerome KR. Cell type-specific induction and inhibition of apoptosis by Herpes Simplex virus type 2 ICP10. Journal of virology. 2009;83(6):2765-9.

30. Heath L, Fox A, McClure J, Diem K, van 't Wout AB, Zhao H, et al. Evidence for limited genetic compartmentalization of HIV-1 between lung and blood. PloS one. 2009;4(9):e6949.

31. Huang Y, Gilbert PB, Montefiori DC, Self SG. Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine Development. Statistics in biopharmaceutical research. 2009;1(1):81-91.

32. Hudgens MG, Gilbert PB. Assessing vaccine effects in repeated low-dose challenge experiments. Biometrics. 2009;65(4):1223-32.

33. Hudgens MG, Gilbert PB, Mascola JR, Wu C-D, Barouch DH, Self SG. Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. The Journal of infectious diseases. 2009;200(4):609-13.

34. Janes H, Longton G, Pepe MS. Accommodating Covariates in ROC Analysis. Stata J. 2009;9(1):17-39.

35. John-Stewart GC, Mbori-Ngacha D, Payne BL, Farquhar C, Richardson BA, Emery S, et al. HV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmission. The Journal of infectious diseases. 2009;199(6):889-98.

36. Johnston C, Orem J, Okuku F, Kalinaki M, Saracino M, Katongole-Mbidde E, et al. Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda. PloS one. 2009;4(1):e4222.

37. Jones NG, DeCamp A, Gilbert PB, Peterson ML, Gurwith M, Cao H. AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection. Vaccine. 2009;27(7):1136-40.

38. Kafulafula G, Mwatha A, Chen YQ, Aboud S, Martinson F, Hoffman I, et al. Intrapartum antibiotic exposure and early neonatal, morbidity, and mortality in Africa. Pediatrics. 2009;124(1):e137-44.

39. Khot PD, Fredricks DN. PCR-based diagnosis of human fungal infections. Expert Rev Anti Infect Ther. 2009;7(10):1201-21.

40. Khot PD, Ko DL, Fredricks DN. Sequencing and analysis of fungal rRNA operons for development of broad-range fungal PCR assays. Appl Environ Microbiol. 2009;75(6):1559-65.

41. Kittikraisak W, van Griensven F, Martin M, McNicholl J, Gilbert PB, Chuachoowong R, et al. Blood and seminal plasma HIV-1 RNA levels among HIV-1-infected injecting drug users participating in the AIDSVAX B/E efficacy trial in Bangkok, Thailand. Journal of acquired immune deficiency syndromes (1999). 2009;51(5):601-8.

42. Kollmann TR, Crabtree J, Rein-Weston A, Blimkie D, Thommai F, Wang XY, et al. Neonatal innate TLR-mediated responses are distinct from those of adults. Journal of immunology (Baltimore, Md : 1950). 2009;183(11):7150-60.

43. Kuypers J, Campbell AP, Cent A, Corey L, Boeckh M. Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients. Transpl Infect Dis. 2009;11(4):298-303.

44. Leung DT, Henning PA, Wagner EC, Blasig A, Wald A, Sacks SL, et al. Inadequacy of plasma acyclovir levels at delivery in patients with genital herpes receiving oral acyclovir suppressive therapy in late pregnancy. J Obstet Gynaecol Can. 2009;31(12):1137-43.

45. Lin C-H, Sloan DD, Dang CH, Wagner T, Cabrera AJE, Tobin NH, et al. Assessment of mitochondrial toxicity by analysis of mitochondrial protein expression in mononuclear cells. Cytometry B Clin Cytom. 2009;76(3):181-90.

46. Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret AS, Baeten J, et al. Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PloS one. 2009;4(4):e5272.

47. Liu Y, McNevin J, Rolland M, Zhao H, Deng W, Maenza J, et al. Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses. The Journal of infectious diseases. 2009;200(12):1825-33.

48. Liu Y, Woodward A, Zhu H, Andrus T, McNevin J, Lee J, et al. Preinfection human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes failed to prevent HIV type 1 infection from strains genetically unrelated to viruses in long-term exposed partners. Journal of virology. 2009;83(20):10821-9.

49. Maclachlan E, Mayer KH, Barnabas R, Sanchez J, Koblin B, Duerr A. The potential role of biomarkers in HIV preventive vaccine trials. Journal of acquired immune deficiency syndromes (1999). 2009;51(5):536-45.

50. Malhotra U, Nolin J, Horton H, Li F, Corey L, Mullins JI, et al. Functional properties and epitope characteristics of T-cells recognizing natural HIV-1 variants. Vaccine. 2009;27(48):6678-87.

51. Marc I, Rainville P, Masse B, Dufresne A, Verreault R, Vaillancourt L, et al. Women's views regarding hypnosis for the control of surgical pain in the context of a randomized clinical trial. J Womens Health (Larchmt). 2009;18(9):1441-7.

52. Martin ET, Taylor J, Kuypers J, Magaret AS, Wald A, Zerr D, et al. Detection of bocavirus in saliva of children with and without respiratory illness. J Clin Microbiol. 2009;47(12):4131-2.

53. Masse B, Boily M-C, Dimitrov DT, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol. 2009;6:5.

54. Mbopi-Keou F-X, Trottier S, Omar RF, Nkele NN, Fokoua S, Mbu ER, et al. A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom formulations in women from Cameroon. Contraception. 2009;80(5):484-92.

55. Mitchell C, Moreira C, Fredricks DN, Paul K, Caliendo AM, Kurpewski J, et al. Detection of fastidious vaginal bacteria in women with HIV infection and bacterial vaginosis. Infect Dis Obstet Gynecol. 2009;2009:236919.

56. Mitchell CM, Hitti JE, Agnew KJ, Fredricks DN. Comparison of oral and vaginal metronidazole for treatment of bacterial vaginosis in pregnancy: impact on fastidious bacteria. BMC Infect Dis. 2009;9:89.

57. Mwinga K, Vermund SH, Chen YQ, Mwatha A, Read JS, Urassa W, et al. Selected hematologic and biochemical measurements in African HIV-infected and uninfected pregnant women and their infants: the HIV Prevention Trials Network 024 protocol. BMC Pediatr. 2009;9:49.

58. Nakamae H, Kirby KA, Sandmaier BM, Norasetthada L, Maloney DG, Maris MB, et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009;15(6):694-703.

59. Paramsothy P, Jamieson DJ, Heilig CM, Schuman PC, Klein RS, Shah KV, et al. The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol. 2009;113(1):26-31.

60. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang M-L, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009;360(12):1191-9.

61. Paulson TG, Maley CC, Li X, Li H, Sanchez CA, Chao DL, et al. Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009;15(10):3305-14.

62. Peng T, Zhu J, Klock A, Phasouk K, Huang M-L, Koelle DM, et al. Evasion of the mucosal innate immune system by herpes simplex virus type 2. Journal of virology. 2009;83(23):12559-68.

63. Pepe MS, Longton G, Janes H. Estimation and Comparison of Receiver Operating Characteristic Curves. Stata J. 2009;9(1):1.

64. Pergam SA, Schmidt DW, Nofchissey RA, Hunt WC, Harford AH, Goade DE. Potential renal sequelae in survivors of hantavirus cardiopulmonary syndrome. Am J Trop Med Hyg. 2009;80(2):279-85.

65. Pine SO, McElrath MJ, Bochud P-Y. Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals. AIDS (London, England). 2009;23(18):2387-95.

66. Qin L, Guo W, Litt B. A Time-Frequency Functional Model for Locally Stationary Time Series Data. Journal of computational and graphical statistics : a joint publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America. 2009;18(3):675-93.

67. Read JS, Mwatha A, Richardson BA, Valentine M, Emel L, Manji K, et al. Primary HIV-1 infection among infants in sub-Saharan Africa: HPTN 024. Journal of acquired immune deficiency syndromes (1999). 2009;51(3):317-22.

68. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. Journal of virology. 2009;83(2):757-69.

69. Sawires S, Birnbaum N, Abu-Raddad L, Szekeres G, Gayle J. Twenty-five years of HIV: lessons for low prevalence scenarios. Journal of acquired immune deficiency syndromes (1999). 2009;51 Suppl 3:S75-82.

70. Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Magaret AS, et al. Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci Transl Med. 2009;1(7):7ra16.

71. Schiffer JT, Corey L. New concepts in understanding genital herpes. Curr Infect Dis Rep. 2009;11(6):457-64.

72. Schiffer JT, Kirby K, Sandmaier BM, Storb R, Corey L, Boeckh M. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica. 2009;94(8):1101-8.

73. Scott JD, Wald A, Kitahata M, Krantz E, Drolette L, Corey L, et al. Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population. AIDS Patient Care STDS. 2009;23(11):925-9.

74. Spearman P, Kalams S, Elizaga M, Metch B, Chiu Y-L, Allen M, et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine. 2009;27(2):243-9.

75. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. Journal of virology. 2009;83(8):3719-33.

76. Sun Y, Gilbert PB, McKeague IW. PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS. Annals of statistics. 2009;37(1):394-426.

77. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant. 2009;44(8):453-5.

78. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009;15(10):1143-238.

79. Toscano CM, Bell M, Zukerman C, Shelton W, Novicki TJ, Nichols WG, et al. Gram-negative bloodstream infections in hematopoietic stem cell transplant patients: the roles of needleless device use, bathing practices, and catheter care. Am J Infect Control. 2009;37(4):327-34.

80. Travi G, Pergam SA, Xie H, Carpenter PA, Kiem H-P, Corey L, et al. The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009;49(11):e120-3.

81. Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, Abraha A, et al. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog. 2009;5(4):e1000365.

82. Verghese PS, Finn LS, Englund JA, Sanders JE, Hingorani SR. BK nephropathy in pediatric hematopoietic stem cell transplant recipients. Pediatr Transplant. 2009;13(7):913-8.

83. Wick WD, Gilbert PB, Yang OO. Predicting the impact of blocking human immunodeficiency virus type 1 Nef in vivo. Journal of virology. 2009;83(5):2349-56.

84. Yang Y, Sugimoto JD, Halloran ME, Basta NE, Chao DL, Matrajt L, et al. The transmissibility and control of pandemic influenza A (H1N1) virus. Science. 2009;326(5953):729-33.

85. Yokoe D, Casper C, Dubberke E, Lee G, Muñoz P, Palmore T, et al. Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated. Bone Marrow Transplant. 2009;44(8):495-507.

86. Yokoe D, Casper C, Dubberke E, Lee G, Muñoz P, Palmore T, et al. Safe living after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44(8):509-19.

87. Zaia J, Baden L, Boeckh M, Chakrabarti S, Einsele H, Ljungman P, et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44(8):471-82.

88. Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med. 2009;15(8):886-92.

89. Zuckerman RA, Lucchetti A, Whittington WLH, Sánchez J, Coombs RW, Magaret AS, et al. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. AIDS (London, England). 2009;23(4):479-83.